- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04094038
The Effect of Intradialytic Parenteral Nutrition on Nutritional Status and Quality of Life in Hemodialysis Patients
July 26, 2022 updated by: Ewout Hoorn, Erasmus Medical Center
Protein-energy wasting (PEW), a hypercatabolic state characterized by loss of muscle mass and fuel reserves, is highly prevalent in hemodialysis patients.
Nutritional status and body composition are closely linked to morbidity, mortality and quality of life.
Lean tissue mass (LTM) appears to be the best read-out for the association between nutritional status and outcomes.
Intradialytic parenteral nutrition (IDPN) is occasionally used with the aim to reduce loss of LTM, but its efficacy has not been established.
The goal of this study is to study the effect of IDPN on changes in LTM in hemodialysis patients.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
166
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David Severs, MD
- Phone Number: +31107040704
- Email: d.severs@erasmusmc.nl
Study Locations
-
-
-
Rotterdam, Netherlands
- Recruiting
- Erasmus MC
-
Contact:
- Ewout J Hoorn
- Phone Number: +31107040704
-
Sub-Investigator:
- David Severs, MD
-
Sub-Investigator:
- Wesley Visser, RD
-
Rotterdam, Netherlands
- Recruiting
- Franciscus Gasthuis & Vlietland
-
Contact:
- Martine Verhoeven, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Undergoing chronic hemodialysis
Exclusion Criteria:
- Life expectancy < 6 months
- Planned kidney transplant within 4 months
- Severe overhydration leading to respiratory insufficiency
- Parenteral nutrition within four weeks prior to screening
- Severe hepatic insufficiency
- Pregnancy
- Unipolar pacemaker with a very low sensitivity threshold
- Active treatment for infection
- Acute myocardial infarction
- Circulatory shock
- Hypersensitivity for any Olimel N12 ingredient or excipient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Intradialytic parenteral nutrition three times weekly during 16 weeks
|
A mixture of glucose, lipids, amino acids.
|
Placebo Comparator: Placebo
5% glucose three times weekly during 16 weeks
|
Glucose 5%
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in lean tissue mass
Time Frame: 16 weeks
|
Measured by body composition monitor (BCM)
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Skeletal muscle quality index (SMQI)
Time Frame: 16 weeks
|
Assessed by muscle ultrasound
|
16 weeks
|
Change in adipose tissue mass from baseline
Time Frame: 16 weeks
|
16 weeks
|
|
Change in hand grip strength from baseline
Time Frame: 16 weeks
|
Measured by hand dynamometer, expressed as percentile of reference (by age and gender)
|
16 weeks
|
Change in kidney disease quality of life (KDQoL-36) energy/fatigue scale from baseline
Time Frame: 16 weeks
|
Assessed by Kidney Disease Quality of Life-36 (KDQoL-36) survey (energy/fatigue scale, 0-100, higher is better)
|
16 weeks
|
Change in kidney disease quality of life (KDQoL-36, overall health rating) from baseline
Time Frame: 16 weeks
|
Assessed by Kidney Disease Quality of Life-36 (KDQoL-36) survey (0-100, higher is better)
|
16 weeks
|
Positive and negative affect
Time Frame: 16 weeks
|
Assessed by Positive and Negative Affect Schedule (PANAS, 0-100, higher is better)
|
16 weeks
|
Change in phase angle from baseline
Time Frame: 16 weeks
|
Assessed by Body Composition Monitor (BCM)
|
16 weeks
|
Change in body weight from baseline
Time Frame: 16 weeks
|
16 weeks
|
|
Change in serum prealbumin concentration from baseline
Time Frame: 16 weeks
|
16 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective global assessment (SGA)
Time Frame: 16 weeks
|
7-point scale, 7 indicates normal nutritional status, 1 indicates severe protein energy wasting
|
16 weeks
|
Change in serum albumin concentration
Time Frame: 16 weeks
|
16 weeks
|
|
Appetite
Time Frame: 16 weeks
|
Numeric rating scale (0-10, 10 being best appetite)
|
16 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ewout J Hoorn, MD PhD, Erasmus Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 16, 2019
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
September 12, 2019
First Submitted That Met QC Criteria
September 16, 2019
First Posted (Actual)
September 18, 2019
Study Record Updates
Last Update Posted (Actual)
July 27, 2022
Last Update Submitted That Met QC Criteria
July 26, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IDPN1
- 2018-003899-13 (EudraCT Number)
- NL65803.078.18 (Other Identifier: Central Commission for Human Research (CCMO))
- MEC-2018-1452 (Other Identifier: Erasmus MC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malnutrition
-
HAN University of Applied SciencesFrieslandCampina; HAS Hogeschool; Centre of Expertise Food (CoE Food); SligroCompletedMalnutrition; Protein | Protein MalnutritionNetherlands
-
International Centre for Diarrhoeal Disease Research...GlaxoSmithKline; Stanford UniversityCompletedMalnutrition | Malnutrition in Children | Child MalnutritionBangladesh
-
University of Nove de JulhoUnknownMalnutrition, ChildBrazil
-
UNICEFSave the ChildrenCompletedSevere MalnutritionCongo, The Democratic Republic of the
-
International Centre for Diarrhoeal Disease Research...UNICEFNot yet recruitingMalnutrition SevereBangladesh
-
Action Against Hunger USAUniversity of Washington; Ethiopian Public Health InstituteNot yet recruitingModerate Acute Malnutrition | Severe Acute Malnutrition
-
Academy of Nutrition and DieteticsHartford Hospital; University of New Mexico; Meals on Wheels Central TexasNot yet recruiting
-
Diego MorettiSwiss Federal Institute of Technology; Wageningen University and Research; St... and other collaboratorsCompletedMalnutrition; ProteinSwitzerland
-
International Centre for Diarrhoeal Disease Research...CompletedProtein MalnutritionBangladesh
-
Microbiome Health Research InstituteUniversity of Cape TownTerminatedModerate Acute Malnutrition | Severe Acute MalnutritionSouth Africa
Clinical Trials on Olimel N12
-
Clinical Evaluation Research Unit at Kingston General...Baxter Healthcare CorporationTerminatedCritical Illness | Acute Respiratory FailureUnited States, Canada, Belgium, France
-
King Faisal Specialist Hospital & Research CenterCompletedHyperphosphatemia | Hyperkalemia | Hypercalcemia | HypermagnesemiaSaudi Arabia
-
University of CalgaryWithdrawnMalnutrition | Inflammatory Bowel Disease 1
-
Fresenius KabiTerminatedCritical IllnessFrance, Germany, Poland
-
RWTH Aachen UniversityClinical Evaluation Research Unit at Kingston General HospitalWithdrawnCritical Illness | Malnutrition | Frailty | Sarcopenia | Nutritional DisorderGermany
-
University Medicine GreifswaldCompletedPancreatic Cancer | Weight Loss | Biliary Tract Cancer
-
University of AlbertaBaxter Healthcare CorporationRecruitingMalnutrition | SurgeryCanada
-
Lawson Health Research InstituteAcademic Medical Organization of Southwestern OntarioCompleted